The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NKP-1339: Maximum tolerated dose defined for first-in-human GRP78 targeted agent.
Dana Shelton Thompson
No relevant relationships to disclose
Glen J. Weiss
No relevant relationships to disclose
Suzanne Fields Jones
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
Ramesh K. Ramanathan
No relevant relationships to disclose
Jeffrey R. Infante
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
Angela Ogden
Employment or Leadership Position - Niiki Pharma, Inc.
Daniel D. Von Hoff
Research Funding - Niiki Pharma, Inc.